CoChat

Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence: Results From a Placebo-Controlled, Double-Blind Trial

Soyka, Michael, Koller, Gabriele, Schmidt, Peggy, Lesch, Otto-Michael, Leweke, Markus, Fehr, Christoph, Gann, Horst, Mann, Karl F. · 2008 · Journal of Clinical Psychopharmacology
Cited by 126

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Multiple lines of evidence suggest that the endocannabinoid system is implicated in the development of alcohol dependence. In addition, in animal models, the cannabinoid receptor 1 blocker rimonabant was found to decrease alcohol consumption, possibly by indirect modulation of dopaminergic neurotransmission. This was a 12-week double-blind, placebo-controlled, proof-of-concept study to assess the possible efficacy of the cannabinoid receptor 1 antagonist rimonabant 20 mg/d (2 x 10 mg) in the prevention of relapse to alcohol in recently detoxified alcohol-dependent patients. A total of 260 patients were included, 258 were exposed to medication, and 208 (80.6%) were men. Patients had an alcohol history of 15 years on average. More patients in the rimonabant group (94/131 [71.8%]) completed treatment compared with the placebo group (79/127 [62.2%]). Although there was a modest effect of rimonabant with respect to relapse rate, there were no statistically significant differences between treatment groups. Approximately 41.5% of the rimonabant group had relapsed to drinking at the end of the study compared with 47.7% of the placebo group (obtained from Kaplan-Meier-curve). Differences were more marked but not statistically significant in patients who relapsed to heavy drinking: 27.7% versus 35.6%, respectively. Safety and tolerance of the drug were good. Similar rates of adverse events were reported between the 2 groups; less patients experienced serious events or discontinued the treatment with rimonabant compared with placebo. Rates of depression-related events were low (3.8% with rimonabant compared with 1.6% with placebo). Patients on rimonabant lost weight (Mean, -1.7 kg) compared with baseline, whereas there was no such change in the placebo group. Weight loss was more pronounced in patients with a higher body mass index. In addition, there was a significant decrease in leptin levels in the rimonabant group compared with baseline. Lack of efficacy in this study may be explained by a very high response rate in the placebo group and a relatively short treatment duration. Taking the substantial numbers of animal studies suggesting a possible role of CB1 antagonists for the treatment of alcohol dependence into account, it seems worthwhile to further test cannabinoid blockers in the treatment of alcoholism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e318172b8bc

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 126

Metadata

Authors
Soyka, M., Koller, G., Schmidt, P., Lesch, O.-M., Leweke, M., Fehr, C., Gann, H., & Mann, K. F.
Venue
Journal of Clinical Psychopharmacology
Published
2008-06
Volume
28
Issue
3
Pages
317-324
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2021211846
Cited by
126
References
10
FWCI
8.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence: Results From a Placebo-Controlled, Double-Blind Trial. https://app.cochat.ai/papers/10.1097/jcp.0b013e318172b8bc
The paper
Soyka, M., Koller, G., Schmidt, P., Lesch, O.-M., Leweke, M., Fehr, C., Gann, H., & Mann, K. F. (2008). Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence: Results From a Placebo-Controlled, Double-Blind Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318172b8bc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.